PremiumThe FlyMerus price target lowered to $70 from $73 at BofA Merus N.V. Reports 2024 Earnings and Clinical Progress Merus’s Promising Clinical Developments and Strategic Advancements Reinforce Buy Rating with $67 Target PremiumRatingsMerus’s Promising Clinical Advances and Breakthrough Therapy Designation Justify Buy Rating Promising Developments in Merus’s Pipeline: Petosemtamab’s Potential in HNSCC and mCRC Merus’s Promising Clinical Developments and Regulatory Progress Justify Buy Rating PremiumThe FlyTarget downgraded, Cisco upgraded: Wall Street’s top analyst calls Analyst Recommends Buy for Merus Based on Promising Petosemtamab Developments and Revenue Potential Merus initiated with an Overweight at Piper Sandler 
